David Dai
Stock Analyst at UBS
(2.14)
# 2,902
Out of 5,124 analysts
29
Total ratings
44.44%
Success rate
-1.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $2.75 | +154.55% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $10.39 | +53.99% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $95.20 | +22.90% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $21.01 | +80.87% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $100.59 | +31.23% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $7.49 | +167.02% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $18.97 | +37.06% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $17.49 | +71.53% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.73 | -26.74% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $10.35 | +131.88% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $34.60 | -30.64% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.80 | +400.00% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $34.57 | +44.63% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $41.52 | +44.51% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $8.42 | +5,220.67% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $79.00 | -49.37% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.61 | +2,384.47% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.85 | +2,602.70% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $28.70 | +81.18% | 1 | Mar 17, 2020 |
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $2.75
Upside: +154.55%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $10.39
Upside: +53.99%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $95.20
Upside: +22.90%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $21.01
Upside: +80.87%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $100.59
Upside: +31.23%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $7.49
Upside: +167.02%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $18.97
Upside: +37.06%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $17.49
Upside: +71.53%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.73
Upside: -26.74%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $10.35
Upside: +131.88%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $34.60
Upside: -30.64%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.80
Upside: +400.00%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $34.57
Upside: +44.63%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $41.52
Upside: +44.51%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $8.42
Upside: +5,220.67%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $79.00
Upside: -49.37%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.61
Upside: +2,384.47%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.85
Upside: +2,602.70%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $28.70
Upside: +81.18%